首页> 外文期刊>Perspectives in Biology and Medicine >Full disclosure: telling patients when not being a research subject is a good choice.
【24h】

Full disclosure: telling patients when not being a research subject is a good choice.

机译:全面披露:告诉患者何时不是研究对象是一个不错的选择。

获取原文
获取原文并翻译 | 示例
       

摘要

Informed consent to participation in research generally requires giving a person information about the alternatives to being in the research study. It is quite common, however, for research subjects not to be given one particularly significant piece of information: the possibility of obtaining the "new" treatment being studied directly from a doctor without participating in the study. Since many people enroll in studies precisely to get such a new treatment, they frequently would prefer that option--which guarantees them that new treatment--to enrolling in a study where there is only a 50% chance of getting the new treatment. This issue becomes more complicated in the context of pediatric oncology research, since physician-researchers in this field have entered into a unique informal agreement not to offer such new treatments outside of research studies. That agreement, which in effect forces physicians to behave in a manner that subordinates the well-being of some of their current patients to that of future patients, is ethically and legally questionable.
机译:知情同意参加研究通常需要向个人提供有关替代研究的信息。然而,很常见的是,没有给研究对象一个特别重要的信息:直接从医生那里获得“新”治疗的可能性而无需参加研究。由于许多人正是为了获得这样的新疗法而精确地参加研究,所以他们通常更喜欢这种选择(这保证了他们获得新疗法),而不是只有50%机会获得新疗法的研究。在小儿肿瘤学研究的背景下,这个问题变得更加复杂,因为该领域的医师研究人员已经达成了一项独特的非正式协议,不得在研究之外提供此类新疗法。该协议实际上迫使医生以某种方式行事,使他们目前的某些患者的健康状况服从于未来患者的健康状况,这在道德和法律上都是值得怀疑的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号